# Alnylam Pharmaceuticals

> Alnylam Pharmaceuticals is a Cambridge, Massachusetts biopharmaceutical company that turned RNA interference from a Nobel-recognized biological mechanism into a commercial class of medicines. It sells four RNAi drugs directly - AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO - earns royalties or collaboration revenue from partner medicines including Leqvio and Qfitlia, and is extending its gene-silencing platform from rare liver-linked disorders into cardiovascular, neurologic and metabolic diseases.

- **Founded:** 2002
- **Headquarters:** Cambridge, United States
- **Founders:** Phillip A. Sharp (Co-founder and scientific adviser), David Bartel (Co-founder), Thomas Tuschl (Co-founder), Paul Schimmel (Co-founder), Phillip Zamore (Co-founder)
- **Team size:** Approximately 2,500 full-time employees as of December 31, 2025
- **Products:** ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran), Leqvio (inclisiran)
- **Notable:** Developed ONPATTRO, the first RNAi therapeutic approved anywhere, in 2018., Six Alnylam-developed RNAi medicines had received approvals by the end of 2025, four commercialized directly and two by partners., Reached its first $1 billion year in net product revenue in 2023.

## Products & services

- **ONPATTRO (patisiran)** — Intravenous RNAi therapeutic for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; the first FDA-approved RNAi medicine.
- **GIVLAARI (givosiran)** — Subcutaneous RNAi medicine for adults with acute hepatic porphyria.
- **OXLUMO (lumasiran)** — Subcutaneous RNAi medicine for primary hyperoxaluria type 1, designed to reduce hepatic production of glycolate oxidase.
- **AMVUTTRA (vutrisiran)** — Quarterly subcutaneous RNAi medicine approved for adults with hereditary ATTR polyneuropathy and, since 2025 in the U.S., cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.
- **Leqvio (inclisiran)** — Alnylam-originated cholesterol-lowering siRNA medicine commercialized globally by Novartis; Alnylam receives royalties.
- **Qfitlia (fitusiran)** — Alnylam-originated antithrombin-lowering siRNA medicine for hemophilia commercialized by Sanofi; approved in the U.S. in 2025.
- **Alnylam Assist** — Patient support services for eligible U.S. patients prescribed Alnylam medicines, including coverage and access navigation.
- **Alnylam Act** — Sponsored third-party genetic testing and counseling for people in the U.S. and Canada with suspected or family histories of selected genetic conditions.

## Achievements

- Developed ONPATTRO, the first RNAi therapeutic approved anywhere, in 2018.
- Six Alnylam-developed RNAi medicines had received approvals by the end of 2025, four commercialized directly and two by partners.
- Reached its first $1 billion year in net product revenue in 2023.
- Reported $2.987 billion in 2025 net product revenue and $3.714 billion in total revenue.
- Achieved full-year GAAP profitability in 2025 after more than two decades of platform investment.
- AMVUTTRA generated more than $1 billion in Q2 2026 product revenue.
- FDA accepted the siRELIS enzymatic ligation manufacturing platform into its Emerging Technology Program in 2025.
- Named one of Fast Company's Most Innovative Companies for 2026 and received MassBio's 2026 Scientific Impact Award.

## Latest updates

- **2026-07** — Reported Q2 global net product revenue of $1.172 billion, including $1.012 billion from AMVUTTRA, and revised full-year TTR product revenue guidance to $4.2-$4.5 billion.
- **2026-07** — Initiated Phase 2 studies of ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer's disease; disclosed a BeOne agreement for AMVUTTRA in mainland China and Macao.
- **2026-06** — Formed an AI discovery collaboration with Inceptive using more than 20 years of proprietary RNAi data.
- **2026-04** — Reported Q1 total revenue of $1.167 billion and GAAP net income of $206 million.
- **2026-03** — Announced collaborations with Viz.ai and support for the American Heart Association aimed at earlier ATTR-CM diagnosis and coordinated care.
- **2026-01** — Launched the Alnylam 2030 strategy centered on TTR leadership, sustained pipeline innovation and disciplined financial growth.

## Links

- Website: https://www.alnylam.com/
- LinkedIn: https://www.linkedin.com/company/alnylam-pharmaceuticals/
- Twitter/X: https://twitter.com/alnylam
- YouTube: https://www.youtube.com/@AlnylamPharmaceuticals
- Instagram: https://www.instagram.com/alnylampharma/
- Facebook: https://www.facebook.com/AlnylamPharma/

---

Profile page: https://yespress.io/alnylam-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-08-11